Acrivon Therapeutics, Inc. (ACRV) has been on a downward spiral lately with significant selling pressure. After declining ...

Acrivon Therapeutics, Inc.’s ACRV share price has dipped by 30.24%, which has investors questioning if this is right time to ...

Acrivon Therapeutics is halting work on developing its lead drug for ovarian and bladder cancers, instead focusing the Eli ...

Oppenheimer lowered the firm’s price target on Acrivon Therapeutics (ACRV) to $10 from $18 and keeps an Outperform rating on the shares ...

Generative Phosphoproteomics AP3 platform designed to enable streamlined, rational drug discovery, with proprietary, proteome-wide SAR delivering ...

Acrivon Therapeutics (NASDAQ:ACRV – Get Free Report) will likely be posting its quarterly earnings results before the market ...

Investors might want to bet on Acrivon Therapeutics, Inc. (ACRV), as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces ...

Cantor Fitzgerald restated their overweight rating on shares of Acrivon Therapeutics (NASDAQ:ACRV – Free Report) in a ...

Acrivon Therapeutics, Inc. (ACRV) has been on a downward spiral lately with significant selling pressure. After declining 52.8% over the past four weeks, the stock looks well positioned for a ...

March 27, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage precision medicine company utilizing its Acrivon ...

Investors might want to bet on Acrivon Therapeutics, Inc. (ACRV), as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful ...